Green Cross Labcell starts world’s first commercialization of NK cell treatment

Published: 2016-01-15 14:12:18

Updated: 2016-01-15 14:12:18

An anticancer therapy, which uses other healthy people’s immune cells not the ones of cancer patients, is expected to be commercialized within in a couple of years for the first time in the world.

On the 13^th, Green Cross Labcell(President Bok-soo Park), a family company of Green Cross in the fields of cord blood and cellular therapy products, announced the Phase 2 clinical trial plan of ‘MG41...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.